SDB-006

SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 50 nM for human CB1 receptors, and 123 nM for human CB2 receptors. It was discovered during research into the related compound APICA which had been sold illicitly as "2NE1". SDB-006 is the indazole core analogue of APICA, and as such is expected to be a potent agonist of the CB1 receptor.

Chemistry

SDB-006 is a synthetic cannabinoid that has been used for its psychoactive effects. It is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor. SDB-006 is related to compounds like AKB48 and STS-135, which are known for their affinity for the CB1 receptor.

Pharmacology

SDB-006 acts as a full agonist with a binding affinity of 1.0nM at CB1 and 2.6nM at CB2 cannabinoid receptors. It is an analogue of APICA, which features an indazole group instead of APICA's indole group.

Legality

In the United States, SDB-006 is a Schedule I Controlled Substance. As of October 2015, SDB-006 is a controlled substance in China.

See also

• Cannabinoid receptor
• APICA
• AKB48
• STS-135

References

SDB-006 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski